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Abstract: Atherosclerosis represents one of the main risk factors for the development of cardiovascular
diseases. Their etiologies have been studied in recent years in order to better define therapeutic
targets for intervention and to identify diagnostic methods. Two different subtypes of macrophages,
M1 and M2, have been described in physiological conditions. They can also be found in the
atherosclerotic process, where they both have opposite roles in disease progression. Perivascular brown
adipose tissue is also involved in inflammation and endothelial damage. In this work, we provide
insights into the protective role of melatonin in the atherosclerotic process by morphological and
18F-FDG-PET/CT analyses. In particular, we examined the effects of melatonin on pathways that
are linked to atherosclerosis development. We showed that melatonin, by suppressing M1 activity,
reduced inflammation and directed macrophage polarization toward the M2 macrophage subtype.
Moreover, melatonin preserved the activity of perivascular brown adipose tissue. In addition,
18F-FDG uptake is very high in mice treated with melatonin, confirming that other factors may alter
18F-FDG distribution. In conclusion, we showed that melatonin affects inflammatory pathways that
have been linked to atherosclerosis, assessed the relationships of the 18F-FDG PET/CT parameters
with macrophage markers and the production of their cytokines, which that have been defined by
morphological evaluations.
Keywords: atherosclerosis; melatonin; macrophage polarization; perivascular brown adipose tissue;
molecular imaging; PET/CT
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1. Introduction
Atherosclerosis has long been known as the main cause of cardiovascular diseases (CVDs)
and only recently, more attention has been paid to the many factors that can contribute to the
development and progression of this process itself [1,2]. Atherosclerosis has a multifactorial
etiology, but it shows similar mechanisms such as chronic inflammation and immune activation [3,4].
In particular, inflammation also activates both innate and adaptive immune responses involving
monocytes/macrophages [5]. M1 macrophages promote plaque development, while M2 macrophages
promote tissue repair and plaque stabilization [6]. More recently, Barrett reported that M1 macrophages
are involved in initiating and sustaining inflammation, while M2 cells are implicated in inflammation
resolution [7]. M2 macrophage enrichment in plaque regression is consistent with the data that M1
cells are pro-atherogenic and promote an unstable plaque [7]. Moreover, it is important to remember
that these cells produce several cytokines [8].
Another fundamental risk factor for atherosclerosis is perivascular adipose tissue [3,9].
Perivascular adipose tissue alterations lead to vascular endothelial and smooth muscle cell dysfunctions.
Moreover, perivascular adipose tissue has characteristics that resemble both brown adipose tissue
(BAT) and white adipose tissue (WAT).
For the reasons reported above, many cardiovascular studies have evaluated the role of adipose
tissue in atherosclerosis progression, focusing on agents that can modulate the inflammatory and
immune pathways. Two of the main scientific points that should be stressed are: (1) most of the
trigger causes leading to atherosclerosis are modifiable, so it is important to find novel therapeutic
interventions with a wider range of action [10], and (2) the current timing of diagnosis and intervention
is not able to assure proper management of the disease. Thus, it is important to evaluate and study
new methods that can recognize and early identify the evolution of this pathologic process [2].
Regarding the first point, many recent studies have focused on how to reduce the progression
of the atherosclerotic process. Among them, particular attention has been paid to melatonin (MLT).
MLT, an indoleamine physiologically produced by the pineal gland mainly during the night as well by
other organs, is often available as a dietary supplement [11–13]. It is involved in several functions and
has powerful antioxidant properties [14–17]. MLT also improves endothelial functions and possesses
anti-inflammatory properties [18]. Moreover, recent evidence has confirmed the role of MLT as a new
agent for atherosclerotic pharmacotherapy.
According to the findings of Høilund-Carlsen et al. and our considerations, it is important
that innovation in diagnostics supports renewal therapies [19]. In particular, the use of
18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) as an imaging modality
for studying inflammation in atherosclerosis is a new, but not well-defined measure of atherosclerotic
plaque [20–22]. It has been identified as a potential new “gold standard” approach for studying
early-stage atherosclerosis considering its non-invasiveness. In fact, this technique allows an early
grading of the disease when it may still be susceptible to therapy [19]. Furthermore, 18F-FDG is
considered as a good indicator of aerobic glycolysis in tumor tissue [23].
Considering the findings above reported, the objectives of this study were (1) to morphologically
confirm and better evaluate the role of MLT in modulating perivascular brown adipose tissue of
apolipoprotein-E knockout (ApoE-/-) mice, a known model of atherosclerosis; and (2) to compare
the morphological evaluations with results obtained with 18F-FDG PET combined with computed
tomography (PET/CT) in order to better define the possible use of these analyses in the detection of
early-stage atherosclerosis and its progression.
2. Results
All animals in both experimental groups were weighed at the beginning and at the end of the
study. There were no statistically significant differences in body weight between the two groups at any
of the weekly measurements across the study duration. Body weight measurements of the control and
MLT-treated groups were 18.0 ± 1.3 g and 18.9 ± 1.5 g at the first time point (p = 0.2) and 38.5 ± 4.0 g
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and 41.8 ± 4.4 g at the last time point (p = 0.13), respectively. In both cases, the last time evaluation
showed significantly increased values as a result of the atherogenic high fat “Western” diet with which
both experimental groups were treated.
2.1. Melatonin Induces Browning of Periaortic Adipose Tissue
Hematoxylin-eosin staining showed the distribution of white and brown adipocytes in the
periaortic adipose tissue of both experimental groups. According to Manieri and colleagues, in fact,
it is possible to find a correspondence between the morphological considerations and the results
obtained from the immunohistochemical evaluations of some proteins used as markers of specific
subpopulation of adipocytes [24]. In the present study, the control group presented larger areas
of periaortic adipose tissue with characteristics of white adipocytes, characterized by unilocular
lipid-laden drops, with a minimum presence of multilocular BAT adipocytes (Figure 1a). In contrast,
the group of MLT-treated mice showed a higher presence of cells with characteristic features of
brown adipocytes, namely multilocular lipid droplets, with a significant reduction of white adipocyte
infiltration (Figure 1b). These data suggest that MLT treatment induced a shift in periaortic adipose
tissue composition from primarily one of white adipocytes to primarily brown adipocytes.
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Figure 1. Morphometrical evaluation. Photomicrographs of the aorta from the control (a,c) and
MLT-treated (b,d) mice. Each panel shows a full-field image at 400× (a,b) (scale bars: 20 µm) and at
1000× (c,d) (scale bars: 10 µm). Control group aorta showed larger areas of WAT, characterized by white
lipid drop, with a minimum presence of multilocular brown adipocytes. In addition, ApoE-/- mice aorta
is also characterized by a disarrangement of normal vascular structure (a). On the contrary, MLT-treated
mice showed a higher presence of BAT, with a significant reduction of white adipocyte infiltration and
are also characterized by relatively unremarkable changes in vascular cytoarchitecture and organization
(b). Photomicrographs of perivascular adipose tissue from the control (c) and from treated (d) mice.
Graphs summarize the morphometrical analyses of the percentage per area of periaortic BAT (e) and
WAT (f) obtained evaluating, for each experimental animal, fifteen non-overlapping fields with the same
area. Statistical analyses comparing multiple continuous outcomes were performed using one-way
analyses of variance test corrected by Bonferroni for morphometrical evaluations. Continuous variables
are summarized as means ± standard deviation. Error bars represent the 95% confidence interval
around the mean; * indicates the level of significance, p ≤ 0.05; black asterisk indicates BAT, brown
adipose tissue; black arrowhead indicates WAT, white adipose tissue; I, tunica intima; M, tunica media;
A, tunica adventitia; CTR, control group; MLT, mice treated with melatonin.
Figure 1c,d show, at higher magnification, the different organization of the periaortic adipose
tissue with respect to the control and MLT-treated groups. The morphometrical analyses of periaortic
BAT (Figure 1e) and WAT (Figure 1f) confirmed the previously reported observations.
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It was also possible to recognize morphological alterations in the aortic wall in the control group
(Figure 1a) due to the presence of atherosclerotic-related lesions. The aortic structural disarrangement
was not evident in the MLT-treated mice (Figure 1b).
2.2. Aortic Inflammatory State
We investigated the expression of the vascular adhesion molecule-1 (VCAM-1) and intracellular
adhesion molecule-1 (ICAM-1) and considered them as general markers of the inflammatory state.
The double immunofluorescence evaluation of VCAM-1 (identified in red staining in Figure 2a,d)
and ICAM-1 (identified in green staining in Figure 2b,e) in the control mice showed a moderate
expression of both adhesion proteins in the tunica intima (merged expression reported in Figure 2c)
instead of an absent/very weak expression at the tunica intima level of ApoE-/- mice treated with MLT
(merged expression reported in Figure 2f).
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Figure 2. Assessment of the inflammatory state. Labelling of the aorta’s wall with VCAM-1 (identified in
red staining, panels (a) and (d) and ICAM-1 (identified in green staining, panels (b) and (e) considering
them as general markers of the inflammatory state. Each panel shows a full-field image at 400×
(scale bars: 20µ ). Double im unofluorescence photomicrograph of the control mice shows a moderate
expression of both adhesion proteins (merged expression reported in panel (c). In contrast, the double
immunofluorescence photomicrograph of ApoE-/- mice treated with melatonin highlights, for the same
inflammatory markers, an absent/very weak positivity at the tunica intima level (merged expression
reported in panel (f). Graphs summarize, as arbitrary units, the positivity, respectively, of VCAM-1
(g) and ICAM-1 (h) obtained, for both adhesion molecules, evaluating fifteen non-overlapping fields with
Int. J. Mol. Sci. 2020, 21, 2920 5 of 18
the same area for each experimental animal. The negative control of the double immunofluorescence
staining without primary antibody and in the presence of isotype matched immunoglobulins G is
reported in (i). Statistical analyses comparing multiple continuous outcomes were performed using a
one-way analyses of variance test corrected by Bonferroni for immunomorphometrical evaluations.
Continuous variables are summarized as means ± standard deviation. Error bars represent the
95% confidence interval around the mean; red arrows indicate the positive staining for VCAM-1;
green arrows indicate the positive staining for ICAM-1; white arrows indicate the double staining
for VCAM-1/ICAM-1; * indicates the level of significance, p ≤ 0.05; I, tunica intima; M, tunica media;
A, tunica adventitia; CTR, control group; MLT, mice treated with melatonin; AU, arbitrary units.
Figure 2g,h respectively report the immunomorphometrical analyses of VCAM-1 and ICAM-1.
Furthermore, Figure 2i shows the negative control of the double immunofluorescence staining.
2.3. Macrophage Population and Related Cytokines
After confirming the role of MLT in reducing inflammation, we wanted to assess the presence of
the aortic macrophage population through the lesion and the aortic wall; in particular, we considered
the expression of the pan-macrophagic marker CD68.
CD68 immunostaining identified both M1 and M2 populations and showed a weak positivity in
the tunica adventitia and subendothelial space of the control mice (Figure 3a). This immunopositivity
slightly decreased in the ApoE-/- treated mice. CD68 expression was lower in the MLT-treated group,
even if not significantly. Moreover, in this group, interestingly, CD68 expression changed its localization,
being mainly evident in the aortic tunica adventitia with respect to the other morphological part of the
aorta (Figure 3b).
To better characterize the macrophage population, CD163, a M2 macrophage marker,
was considered. CD163 expression was negative or really weak in the control mice (Figure 3d),
being, on in contrast, moderately/strongly expressed in both the subendothelial space and tunica
adventitia of MLT-treated mice (Figure 3e).
Through the expression of CD68 and CD163, the presence of both M1 and M2 macrophages and,
specifically, of CD163 M2 macrophages were evaluated. Then, the number of CD68 cells and CD163
macrophages were considered and are reported in Figure 3c,f, respectively.
Finally, Figure 3g,h show the CD68 and CD163 immunohistochemical negative controls, respectively.
To better define the macrophage’s role in atherosclerosis, we evaluated the expression of tumor
necrosis factor-α (TNF-α; identified in green staining in Figure 4a,b) and of transforming growth
factor-β (TGF-β; identified in green staining in Figure 4d,e), which are markers of M1 and of M2
activity, respectively.
Results confirmed that control mice were characterized by an infiltrate of macrophages
predominantly polarized in the M1 direction and showed a moderate TNF-α expression at
subendothelial and adventitia levels (Figure 4a). In contrast, the positivity for the same M1 marker
was absent/very weak in ApoE-/- mice treated with MLT (Figure 4b).
In conclusion, the TGF-β study validated what was previously shown by CD163 positivity: as a
cytokine mainly associated with M2 polarization, its expression was absent in the aorta of the control
mice (Figure 4d), while the MLT-treated mice showed a moderate TGF-β expression in the tunica
adventitia (Figure 4e).
Figure 4c,f report the immunomorphometrical analyses of TNF-α and TGF-β, respectively.
Finally, Figure 4g,h show the TNF-α and TGF-β immunofluorescence negative controls, respectively.
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Figure 3. Immunohistochemical characterization of macrophage population. Labelling of the
aorta’s wall with CD68 (a,b) and CD163 (d,e) antibodies. Each panel shows a full-field image
at 1000× (scale bars: 20 µm). Immunohistochemical photomicrograph shows the positivity for
CD68, mainly localized in the subendothelial space and in the tunica adventitia of control mice
(a). In contrast, the immunohistochemical photomicrograph of ApoE-/- mice treated with melatonin
highlights that this immunopositivity slightly decreased in the subendothelial space, even if not
significantly, after melatonin supplementation (b). CD163 expression was negative or really weak
in control mice (d). In contrast, the photomicrograph of MLT-treated mice showed that CD163 was
moderately/strongly expressed both in the subendothelial space and tunica adventitia, increasing its
positivity after melatonin administration (e). Graphs summarize the number of CD68 (c) and CD163
(f) positive cells, obtained for both macrophage markers, evaluating five non-overlapping fields with the
same area from three non-consecutive aorta sections. For both CD68 (g) and CD163 (h), sections without
primary antibody and in the presence of isotype matched immunoglobulins G served as negative
immunohistochemical controls. Statistical analyses comparing multiple continuous outcomes were
performed using one-way analyses of variance test corrected by Bonferroni for immunomorphometrical
evaluations. Continuous variables are summarized as means ± standard deviation. Error bars represent
the 95% confidence interval around the mean; * indicates the level of significance, p ≤ 0.05; black arrow
indicates CD68 positive macrophage; black arrowhead indicates CD163 positive M2 macrophage;
I, tunica intima; M, tunica media; A, tunica adventitia; AP, atherosclerotic plaque; CTR, control group;
MLT, mice treated with melatonin.
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Figure 4. Immunofluorescence characterization of macrophage cytokine production. Labelling of
the aorta’s wall with TNF-α (a,b) and TGF-β (d,e) antibodies. Each panel shows a full-field image
at 400× (scale bars: 20 µm). Immunofluorescence photomicrograph of control mice showed a
moderate TNF-α expression at the subendothelial and adventitia levels, confirming that these mice
were characterized by an infiltrate of macrophages predominantly polarized in the M1 direction (a).
In contrast, the immunofluorescence photomicrograph of ApoE-/- mice treated with melatonin highlights,
for the same M1 marker, an absent/very weak positivity (b). Immunofluorescence photomicrograph
also showed an absent expression of TGF-β in the aorta of the control mice (d). Differently,
the immunofluorescence photomicrograph of MLT-treated mice showed a moderate TGF-β expression
in the tunica adventitia (e). Graphs summarize, as arbitrary units, the immunomorphometrical
analyses of TNF-α (c) and TGF-β (f) obtained, for both pro-inflammatory markers, evaluating fifteen
non-overlapping fields with the same area for each experimental animal, respectively. For both
TNF-α (g) and TGF-β (h), sections without primary antibody and in the presence of isotype matched
immunoglobulins G served as negative immunofluorescence controls. Statistical analyses comparing
multiple continuous outcomes were performed using one-way analyses of variance test corrected
by Bonferroni for immunomorphometrical evaluations. Continuous variables are summarized as
means ± standard deviation. Error bars represent the 95% confidence interval around the mean;
* indicates the level of significance, p ≤ 0.05; red arrows indicate the positive staining for TNF-α; green
arrows indicate the positive staining for TGF-β; I, tunica intima; M, tunica media; A, tunica adventitia;
CTR, control group; MLT, mice treated with melatonin; AU, arbitrary units.
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2.4. Aortic 18F-FDG PET/CT Evaluation
On the baseline PET/CT images, mean aortic 18F-FDG uptake, expressed as mean %ID/mL
(%injected dose per mL of tissue) was not significantly different between the control (2.6 ± 0.6 %ID/mL)
and MLT-treated (2.3 ± 0.4 %ID/mL) groups (p = 0.5) (Figure 5a). Interestingly, after 14 weeks
of atherogenic diet, follow-up PET/CT scans demonstrated significantly higher (p = 0.049) mean
aortic 18F-FDG uptake in the MLT-treated group (2.9 ± 0.9 %ID/mL) compared to the control group
(1.9 ± 0.3 %ID/mL) (Figure 5b).
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from biodistribution data (c). The latter was divided by 105 for the purpose of visualization. Error bars
represent the 95% confidence interval around the mean; * indicates the level of significance, p ≤ 0.05;
CTR control group; MLT, mice treated with melatonin; %ID/mL, % injected dose per mL of tissue;
pCi/g, picocurie per gram.
18F-FDG activity concentration detected in the aorta, counted immediately after 14 weeks PET
scans, showed higher values for the MLT-treated group (4 ± 4.1 × 105 pCi/gm) compared to the control
group (1.9 ± 1.0 × 105 pCi/gm), even if with no statistically significant differences (p = 0.2) (Figure 5c).
The images obtained from the first scan (baseline) and after 14 weeks of atherogenic diet (follow-up)
are reported in Figure 6: sagittal views of the control mouse (Figure 6a,b) were compared with those
obtained from the MLT-treated mouse (Figure 6c,d). Each panel (Figure 6a–d) showed, from left to
right, CT only, PET only, and fused PET/CT images, respectively. The liver can be recognized as a
large solid structure in the CT image and vertebral column as a hyperdense (white) posterior structure.
The heart and the urinary bladder can be identified as the sites with the most intense activity in the
PET and fused PET/CT images, while the brain may demonstrate variable levels of 18F-FDG uptake.
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Figure 6. 18F-FDG PET/CT evaluation. Sagittal views of MLT-treated mouse (c,d) and comparable
views of a control mouse (a,b). Each panel shows, from left to right, CT only, PET only, and fused
PET/CT images. Liver is recognized as a large solid structure in CT image and vertebral column as
a hyperdense (white) posterior structure. In PET and fused PET/CT images, the sites with the most
intense activity are the heart and the urinary bladder due to the normal excretion of 18F-FDG by the
kidneys (not shown in this section). The brain may demonstrate variable levels of 18F-FDG uptake.
The structure lying anterior to the vertebral column represents the abdominal aorta. Mild 18F-FDG
uptake is seen in its proximal part at the baseline PET/CT images taken from the control (a) and
MLT-treated (c) mice. After 14 weeks of the atherogenic diet, a second PET/CT scan showed nearly
unchanged FDG activity in the control mice (b) while, the MLT-treated group presented a significantly
higher 18F-FDG uptake in the same region of the aorta (d) compared to the baseline (respectively (a) for
the control group and c for the MLT-treated mice). %ID/cc %injected dose per mL of tissue; white arrow
indicates the liver; two orange arrowheads indicate the vertebral column; white asterisk indicates
the heart; two white asterisks indicate the urinary bladder; white dashed circle indicates the brain;
white arrowhead indicates the abdominal aorta.
The structure lying anterior to the vertebral column represents the abdominal aorta, the specific
site analyzed during this study. Mild 18F-FDG uptake has been detected in its proximal part at
the baseline PET/CT images taken from the control (Figure 6a) and MLT-treated (Figure 6c) mice.
After 14 weeks of the atherogenic diet, the second PET/CT scan showed significantly higher 18F-FDG
uptake in the same region of the aorta in the MLT-treated group (Figure 6d). In contrast, in the control
group, the segment representing the abdominal aorta appeared nearly unchanged in FDG activity
(Figure 6b) compared to the baseline (Figure 6a).
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3. Discussion
In this work we provided insights into the protective role of MLT in the development of
atherosclerotic process by morphological and 18F-FDG-PET/CT analyses.
The effects of MLT that have already been reported by many authors as well as our group [13,25,26],
showed that this indoleamine is able to act on inflammation. Here, we demonstrated that
ApoE-/- mice treated with MLT had unremarkable morphological changes and very low atherogenic
marker expression.
Of particular interest is to note that the morphological analyses showed that the ApoE-/-
MLT-treated mice had a higher number of M2 macrophages with respect to the M1 cells and the control
animals. These animals also showed a high amount of BAT activity with respect to the control mice.
These findings are in line with previous evidence reporting that the macrophage subtypes have several
roles in immune response due to their innate ability to adapt to the microenvironmental changes of the
host [27]. Furthermore, a compelling clinical study showed that both subtypes were evident in human
plaques, but M2 macrophages were localized in a stable position inside the lesion, and the expression
of their markers was inversely related with disease progression. M1 macrophages were abundant in
vulnerable plaques whereas M2 cells were fewer in the atherosclerosis animal model. Both of these
populations are plastic cells because they can switch from the M1 to M2 state and vice versa upon
specific signals; the changes from M1 to M2 has been defined as “macrophage polarization” [28].
Furthermore, M1 macrophages exhibit elevated lipid accumulation, which contribute to the acceleration
of atherosclerosis; whereas in contrast, M2 macrophages are located far from the lipid core of the plaque,
contain smaller lipid droplets, and are involved in phagocytosis [29–31]. In particular, Chinetti et al.
showed that in the adventitia, M2 macrophages are twofold to threefold more abundant than M1
macrophages [29]. Moreover, it has been shown that in ApoE-/- mice, the major site of vascular
inflammatory cell accumulation is adventitia rather than the intima, and in atherosclerotic human
aorta, inflammatory cells were observed to be present in perivascular adipose tissue at the adventitial
margin [32,33]. Furthermore, Moos et al. demonstrated that in atherosclerotic arteries, the lamina
adventitia is a major compartment of wall inflammation with lymphocyte infiltration and lymphoid
follicle-like organogenesis [32]. Therefore, it is possible that the increase of M2 macrophages, stimulated
by MLT, is necessary for reducing the atherosclerotic process. This hypothesis could be linked to
the functions of these cells, which are related to anti-inflammatory expression markers, as reported
by Yang et al. [34]. To support this hypothesis, some researchers have shown that MLT ameliorates
inflammation by suppressing the cells toward the pro-inflammatory M1 phenotype and circadian
nuclear receptor.
WAT mass or activity is positively correlated with the development of some diseases (e.g., obesity and
type 2 diabetes) because it stores surfeit lipid, rendering the macromolecules in adipocytes particularly
vulnerable to carbonylation and other modifications driven by oxidative stress. On the contrary, BAT
is negatively correlated with the diseases reported above; it is a metabolically active fat with both local
and systemic antiatherogenic effects [35–37]. Furthermore, it is known that BAT metabolism daily and
seasonal variations are regulated by MLT through not well-known mechanisms [38,39]. Our data indicate
that the aorta of the atherosclerotic mice model had more periaortic WAT with respect to the same animals
treated with MLT. Instead, these animals showed a greater amount of periaortic BAT.
All data reported above corroborate our findings suggesting that MLT plays an important role
in the reduction/suppression of the atherosclerotic process; this indoleamine is able to stimulate M2
macrophages, the production of their cytokines, and preserve periaortic BAT activity, which is crucial
for organism homeostasis [39].
Another important finding of this study is the possibility of extending the vasoprotective effects
of MLT on atherosclerosis, showing that 18F-FDG can be used to measure the progression of the
atherosclerotic process as well as measure the periaortic BAT activity. The evidence to support this
interpretation is not complete [22]. Thereby, detailed studies in this direction could be the key for
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demonstrating the capacity of the 18F-FDG marker and stressing the benefits of MLT with an easy
technical approach.
Our findings suggest that 18F-FDG uptake is very high in mice treated with MLT and these data do
not seem to be in line with the morphological data on atherosclerotic progression. Therefore, aimed at
this purpose, we wanted to consider, first at all, the diagnostical characteristics of the 18F-FDG marker
and, second, compare the morphological results with clinical data.
Several studies have shown that 18F-FDG is used as a diagnostic marker to reveal physiological or
pathological glucose metabolism changes at the molecular level [40]. This agent has sensitivity and
accuracy for tumor diagnosis, staging, and treatment response [41]. Moreover, some researchers have
studied the 18F-FDG marker in normal tissues and some factors that can influence its uptake such as
age, gender, and blood glucose [42,43].
However, it is possible that other factors that may alter 18F-FDG distribution are not
well-known [39]. In this context, our study supports the last hypothesis; in fact, we showed that
18F-FDG uptake is very weak in the atherosclerotic mice model, but high in the same animals treated
with MLT. The focus on these findings could be linked to the increased number of M2 macrophages and
to the high activity of BAT, which have been seen by morphological analyses. Therefore, the presence
of M2 macrophages and periaortic BAT can be other factors involved in 18F-FDG uptake. Na and Choi
proposed that the M2 macrophage enrichment score was positively correlated to 18F-FDG uptake in
advanced head and neck squamous cell carcinoma [44]. According to these authors, the competition for
glucose between cancer and immune cells plays an important role in the tumor progression associated
with hypermetabolic characteristics.
Regarding periaortic BAT activity, several studies have suggested a relation between total volume
of activated BAT, evaluated by 18F-FDG-PET/CT, and a positive prognostic factor of tumor [45,46].
They demonstrated that 18F-FDG uptake was due to periaortic BAT metabolic activity, which interferes
with oncological conditions. From this point of view, our observations obtained by 18F-FDG marker
were consistent with the studies reported above and showed a positive network with morphological
analyses. Moreover, there have been many experimental studies reporting that this method is used to
evaluate atherosclerosis in mouse atherosclerosis models [47,48]. These data raise questions about
the use of 18F-FDG-PET/CT in ApoE-/- mice, indicating that periaortic adipose tissue is a confounding
factor for atherosclerosis. Our data were in agreement with these results, showing that 18F-FDG uptake
is linked to adipose tissue. MLT increases periaortic BAT and this confirms the evidence of the benefits
conferred by the stimulation of this tissue, giving a further demonstration of its possible therapeutic
role as reported by Oliver et al. [49].
In conclusion, the present study demonstrated that MLT could be considered a “therapeutic”
strategy for atherosclerosis, but the very important findings regard the possibility of using
18F-FDG-PET/CT for monitoring and/or management of non-neoplastic applications.
Last but not least, our study stresses how two different approaches such as morphological and
imaging data lead to the same results, suggesting that 18F-FDG is a sensitive marker even for marking
changes associated with the homeostasis of the organism. In this case, the marker also seems to be,
accurate for elucidating the beneficial effects of MLT in atherosclerotic processes by demonstrating
increased periaortic BAT mass and M2 polarization.
4. Materials and Methods
4.1. Animals and Treatments
All animal experiments were conducted upon approval (17 December 2015) of the University
of California, San Francisco (UCSF) Institutional Animal Care and Use Committee (IACUC) and
supervision of the Laboratory Animal Research Center (LARC), which is accredited by the Association
for Assessment and Accreditation of Laboratory Animal Care International (AAALAC International).
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A total of 20 ApoE-/- mice (JAX B6.129P2-Apoetm1Unc/J, strain #003000, The Jackson Laboratory,
Bar Harbor, ME, USA) were studied. Since the 4th week of life, all mice were treated with an
atherogenic high-fat “Western” diet (0.2% total cholesterol, saturated fat >60% total fat and high
sucrose; TD 88137, Harlan Teklad, Harlan Laboratories, Madison, WI, USA) for the entire duration of
the study (14 weeks) to expedite the development of atherosclerotic process; all mice had free access to
food. When the atherogenic diet started, mice were randomly assigned to two different groups: the
first group (10 mice) was treated with MLT (Melapure™, Flamma S.p.A., Chignolo d’Isola – BG, Italy)
dissolved in a minimum volume of ethanol (0.7–0.9% of the final solution) and diluted in drinking
water to yield the final dose of 10 mg/kg body weight/day. The dose selection was based on previous
studies, showing a preventive effect of MLT administration on endothelial dysfunction at a dose level of
10 mg/kg/day [50,51]. The second group (10 mice) was treated orally with drinking water plus vehicle
of MLT (ethanol). The sample size was obtained through the analyses of the factorial variance with a
fixed effect model and to reach the power of 0.82 at a significance of 0.05, 10 animals per experimental
group were used.
Each mouse was identified by a unique ear-notch punch without a metal ear tag in order to
avoid a metal artifact in CT; in addition, mice were monitored daily for wounds or signs of distress
and weekly for weight changes. All mice were euthanized at the end of the study by anesthetic
overdose (5% isoflurane) followed by cervical dislocation, conforming to the standard established by
the UCSF LARC.
4.2. Histopathological Analyses
Aorta specimens from the abdominal tract were rinsed in physiological solution and used for the
morphometrical, immunohistochemical, and immunofluorescences analyses. They were fixed in 4%
buffered paraformaldehyde for 24 h, dehydrated in graded ethanol, and then embedded in paraffin
wax, following the standard protocol [50,52]. Serial paraffin Sections (7 µm thick) of each sample were
cut with a microtome.
4.3. Morphometrical Analyses
Alternate paraffin sections were dewaxed, rehydrated, and stained with hematoxylin-eosin,
following the standard protocol. Fifteen non-overlapping fields with the same area (0.04 µm2/field)
and randomly selected for each experimental animal were observed with an optical light microscope
(Olympus, Hamburg, Germany) in order to evaluate periaortic BAT and WAT. In particular,
brown adipocytes have been recognized thanks to their characteristic multilocularity and abundance
of big typical mitochondria. Moreover, they are morphologically and functionally different from white
adipocytes: BAT is mainly composed of small, polygonal cells with ~50% of the volume occupied
by lipids partitioned into several droplets, on the contrary, the parenchyma of WAT is composed of
unilocular, lipid-laden white adipocytes, characterized by only few and small mitochondria and by
few sympathetic noradrenergic nerve fibers [24,53].
Histological whole-slide images were obtained at the magnitude of 400 and 1000 times the original
size, using a QImaging QICAM digital camera (High-Performance IEEE 1394 FireWire™ Digital CCD
Camera, 1.4 million pixels, 12-bit digital output, Surrey BC, Canada V3S 6K3) and an optical light
microscope (Olympus, Hamburg, Germany) application supplied by the manufacturers.
The percentage per area of periaortic BAT and WAT was calculated using computerized image
analyzing software (Image Pro Premier 9.1, MediaCybernetics, Rockville, MD, USA).
Two blinded investigators performed the morphometrical analyses using an image analyzer;
in the case of dispute concerning interpretation, the case was reviewed to reach an agreement.
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4.4. Immunofluorescence, Immunohistochemistry, and Immunomorphometrical Analyses
Alternate paraffin sections were dewaxed, rehydrated, and incubated in 3% hydrogen peroxide
for 30 min. Then, after the blocking step in 3% bovine serum albumin solution for 1 h, the sections
were incubated 1 h at 37 ◦C and 30 min at room temperature with the following primary antibodies:
rat monoclonal antibody against CD68 (diluted 1:100; Abcam, Cambridge, UK); rabbit polyclonal
antibody against CD163 (diluted 1:50; Abcam, Cambridge, UK); goat polyclonal antibody against
TNF-α (diluted 1:200 Santa Cruz Biotechnology Inc., Dallas, TX, USA) [54]; mouse monoclonal antibody
against TGF-β (diluted 1:150; Santa Cruz Biotechnology Inc., Dallas, TX, USA) [55] and simultaneously
with mouse monoclonal antibody against ICAM-1 (diluted 1:200; Santa Cruz Biotechnology Inc., Dallas,
TX, USA) and rabbit polyclonal antibody against VCAM-1 (diluted 1:200; Santa Cruz Biotechnology
Inc., Dallas, TX, USA). For immunofluorescence analyses of TNF-α, TGF-β, ICAM-1, and VCAM-1,
the sections were labelled with specific conjugated secondary antibodies (diluted 1:200; Invitrogen,
Paisley, UK), counterstained with 4′,6-diamidino-2-phenylindole (DAPI), mounted, and observed
with a fluorescent microscope (Nikon, Düsseldorf, Germany) with red/green/blue filters at final
magnification of 400× [56–58].
For immunohistochemical analyses of CD68 and CD163, the aorta sections were sequentially
incubated in specific biotinylated immunoglobulins and in avidin-biotin peroxidase complex.
The reaction products were visualized using 0.33% hydrogen peroxide and 0.05% 3,3′-diaminobenzidine
tetrahydrochloride as the chromogen. The sections were finally counterstained with hematoxylin,
mounted, and observed with a light microscope (Olympus, Hamburg, Germany) at a final magnification
of 1000×.
Sections without primary antibody and in the presence of isotype matched immunoglobulins
G served as negative immunofluorescent/immunohistochemical controls. In detail, the double
immunofluorescence negative control was obtained with a mixed solution of secondary antibodies.
Fifteen non-overlapping fields with the same area (0.04 µm2/field) and randomly selected for
each experimental animal were analyzed and the immunopositivity for each primary antibody was
calculated using a computerized image analyzer software (Image Pro Premier 9.1, Media Cybernetics,
Rockville, MD, USA). The immunopositivity for each primary antibody was calculated as integrated
optical density (IOD) automatically compared to the area considered. The IOD value reports the
average intensity/density of each stained region and it was expressed by the software as arbitrary units
(AU) [59,60]. Furthermore, the number of CD68 and CD163 positive cells were counted in randomly
selected five non-overlapping fields with the same area (0.04 µm2/field) from three non-consecutive
aorta sections for each experimental animal [59,60]. Two blinded investigators performed the
immunomorphometrical analyses and, again, in case of dispute concerning interpretation, the case
was reviewed to reach an agreement.
4.5. 18F-FDG PET Imaging and Biodistribution
Mice were fasted with ad libitum access to beverage at least for 6 h before receiving
10.1 ± 0.45 MBq/kg of FDG in 0.1 mL volume via tail vein. All mice were imaged at the baseline
(the day before starting the atherogenic diet) and after 14 weeks of the atherogenic diet.
Twenty mice completed 18F-FDG PET/CT scans at the baseline but only nineteen completed
18F-FDG PET/CT scans at the follow-up time point.
The PET data were acquired 60 min after radiotracer administration with a single 20-min bed
position, followed by CT for attenuation correction of PET reconstruction. Animals were kept at
room temperature during uptake time and scan, and under anesthesia with 2% isoflurane mixed with
medical grade oxygen.
All scans were performed on a dedicated small animal PET/CT scanner (Inveon, Siemens Healthcare,
Malvern, PA, USA). PET images were reconstructed using the ordered subsets expectation maximization
(OSEM) algorithm, provided by the manufacturer. The resulting PET images had a 128 × 128 × 159
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matrix with a voxel size of 0.776 × 0.776 × 0.796 mm3. CT images were reconstructed using a cone-beam
Feldkamp reconstruction algorithm (COBRA, Exxim Computing Corporation, Pleasanton, CA, USA).
The reconstructed CT images had a 512 × 512 × 662 matrix size with an isotropic voxel size of 0.191 mm3.
The coregistered attenuation map from CT, obtained via a pre-derived rigid transformation matrix,
was used for attenuation correction of the PET data.
Following each scan, investigators monitored the animals carefully until they fully recovered
from anesthesia before being held in the animal vivarium again. The experimental protocol of the
research project was designed to provide the minimum level of pain or suffering, consistent with the
objectives of the project.
Aorta images obtained at each time point were reviewed, then the 3D freehand tool in
Amide software [61] was used to delineate volumes of interest (VOIs) on the aorta, on axial
slices. Percent-injected dose per milliliter (%ID/mL) was used to quantify the FDG measurements.
Both maximum and mean values were obtained and averaged over the delineated VOIs.
Furthermore, biodistribution studies were conducted immediately after the 14-week scan.
After euthanizing the animals, blood samples were obtained by cardiac puncture. Thirteen samples
(including the aorta, heart, lung, liver, stomach, small intestine, large intestine, pancreas, spleen, kidney,
muscle, brain, and bone) were removed, rinsed in water, and dried in air for 5 min. The samples were
then weighed and counted on a gamma-counter (1470 WIZARD Gamma Counter, Wallac, Finland) for
accumulation of 18F-FDG. The uptake of radiotracer in tissues was expressed in counts per minute
corrected for decay and background and expressed as picocurie per gram (pCi/g).
4.6. Statistical Analyses
Statistical analyses were performed with SPSS (Version 22.0, IBM Corp., Armonk, NY, USA) using
a two-sided 0.05 level of significance. Student’s t-test (for numerical and approximately normally
distributed data) and Mann–Whitney U tests (for numerical and not normally distributed data) were
used to evaluate differences in the animal’s characteristics between the MLT-treated and control groups.
Statistical analyses comparing multiple continuous outcomes were performed using the one-way
analyses of variance test corrected by Bonferroni for morphometrical and immunomorphometrical
evaluations. Continuous variables were summarized as means ± standard deviation.
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Abbreviations
CVDs Cardiovascular diseases
TNF-α Tumor necrosis factor-α
TGF-β Transforming growth factor-β
WAT White adipose tissue
BAT Brown adipose tissue
MLT Melatonin
18F-FDG 18F- fluorodeoxyglucose
PET Positron emission tomography
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CT Computed tomography
UCSF University of California, San Francisco
IACUC Institutional Animal Care and Use Committee
LARC Laboratory Animal Research Center
AAALAC Association for Assessment and Accreditation of Laboratory Animal Care
ApoE-/- Apolipoprotein-E knockout
OSEM Ordered subset expectation maximization
VOIs Volumes of interest
%ID/ml %injected dose per ml of tissue
pCi/g Picocurie per gram
CD68 Cluster of Differentiation 68
CD163 Cluster of Differentiation 163
ICAM-1 Intracellular adhesion molecule-1
VCAM-1 Vascular cellular adhesion molecule-1
DAPI 4′,6-diamidino-2-phenylindole
AU Arbitrary units
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